Cells of Benign and Borderline Thyroid Tumor Express Malignancy Markers

We studied expression of malignancy markers galectin-3, cytokeratin-19, HBME-1, fibronectin, and cyclin D1 in cells of benign ( n =51), malignant ( n =87), and borderline ( n =53) tumors. The results indicate that 3.9% benign and 41.5% borderline tumors express malignancy markers (specificity 98-100...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bulletin of experimental biology and medicine 2016-03, Vol.160 (5), p.698-701
Hauptverfasser:	Abrosimov, A. Yu, Dvinskikh, N. Yu, Sidorin, A. V.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Biomarkers, Tumor - biosynthesis Biomedical and Life Sciences Biomedicine Cell Biology Cyclin D1 - biosynthesis Development and progression Diagnosis Female Fibronectins Fibronectins - biosynthesis Galectin 3 - biosynthesis Humans Immunohistochemistry Internal Medicine Keratin Keratin-19 - biosynthesis Laboratory Medicine Male Pathology Thyroid diseases Thyroid Gland - pathology Thyroid Gland - surgery Thyroid Neoplasms - pathology Thyroid Neoplasms - surgery Tumors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We studied expression of malignancy markers galectin-3, cytokeratin-19, HBME-1, fibronectin, and cyclin D1 in cells of benign ( n =51), malignant ( n =87), and borderline ( n =53) tumors. The results indicate that 3.9% benign and 41.5% borderline tumors express malignancy markers (specificity 98-100%). Follow up over 1-10 years after surgical treatment for borderline tumors showed no progression of tumor growth. We conclude that some benign and borderline tumors represent low-grade neoplasms with favorable prognosis.
ISSN:	0007-4888 1573-8221
DOI:	10.1007/s10517-016-3253-1